Background
The underlying dispute concerned HAPVIDA’s refusal to cover cancer treatment prescribed by a physician for one of its health insurance beneficiaries. The claimant sought to compel coverage and recover damages for the insurer’s denial. The lower court ruled in favor of the claimant, holding that cancer treatment coverage is mandatory under HAPVIDA’s policy and under established STJ precedent, regardless of whether the specific treatment might be considered off-label or experimental.
HAPVIDA then filed a special appeal (Recurso Especial) to the Superior Tribunal de Justiça challenging this ruling. In its special appeal, HAPVIDA argued that the lower court had applied cancer coverage requirements mechanically without analyzing the specific factual circumstances—contending that the treatment in question fell outside the scope of the insurance contract and regulatory guidelines. The STJ’s Third Panel dismissed HAPVIDA’s special appeal on the merits, upholding the lower court’s judgment.
Dissatisfied, HAPVIDA filed an internal appeal (agravo interno) against the Third Panel’s decision denying the special appeal. This appeal is the subject of the present ruling.
The Court’s Holding
The Third Panel unanimously dismissed HAPVIDA’s internal appeal without reaching the merits. The court held that under Article 1.021 of the New Code of Civil Procedure (NCPC), an internal appeal may be filed only against decisions rendered by a single judge (monocrática), not against decisions issued by a collegial body or panel. HAPVIDA’s attempt to challenge the Third Panel’s decision—which was a collegial decision—constituted an improper use of the internal appeal remedy and amounted to a “gross error” (erro grosseiro).
The court held that the principle of appellate fungibility—which allows courts to recharacterize one appeal as another when the parties’ intent is clear—cannot be applied to cure such a gross procedural error. The court also emphasized that filing a manifestly inadmissible appeal does not suspend or interrupt deadlines for filing other permissible appeals. Consequently, the court immediately certified the judgment as final and ordered the case remanded to the court of origin for execution.
Key Takeaways
- Under Brazilian procedural law, the internal appeal (agravo interno) is exclusively available to challenge single-judge decisions; it cannot be used against collegial panel decisions.
- Filing an internal appeal against a panel decision is a gross error that makes the appeal incabível (inadmissible), and the principle of appellate fungibility cannot be invoked to correct this defect.
- Filing a manifestly inadmissible appeal does not toll or suspend the deadlines for filing other appeals, and the case proceeds to finality immediately.
- The STJ has established consistent precedent on this procedural requirement and applies it strictly.
Why It Matters
While this decision is fundamentally procedural, it reinforces the strict application of appellate rules in the Brazilian judicial system. The underlying substantive issue—whether health insurers may refuse to cover cancer treatments prescribed by physicians on the ground that they are off-label, experimental, or outside contractual scope—is a significant question in Brazilian health law. However, because HAPVIDA chose an improper procedural avenue, the STJ never addressed this question on the merits. The original judgment compelling HAPVIDA to cover the treatment remains in force.
For health insurers and litigants in Brazil’s superior courts, this decision serves as a reminder that procedural precision is mandatory: filing the wrong type of appeal at the wrong level, even with strong substantive arguments, will result in dismissal without consideration of the underlying issues. The decision also illustrates the court’s unwillingness to apply doctrines of flexibility (such as fungibility) when doing so would effectively eliminate the procedural safeguards that structure appellate review.